 "Natco Pharma Q1 net up 28% at Rs 22 cr")
The company had posted a net profit of Rs 17.07 crore for the corresponding period previous fiscal, Natco Pharma said in a filing to BSE.
Consolidated total income from operations of the company rose to Rs 172.51 crore for the quarter under consideration from Rs 140.84 crore for the same period year ago.
Also Read
Exports of active pharmaceutical ingredients (APIs) and finished dosage pharmaceutical formulations continue to drive the growth, Natco Pharma said.
"With a favourable verdict having been received from the Federal Circuit Court, the company is awaiting US FDA approval of its ANDA for Glatiramer Acetate (Copaxone) for a possible launch in May 2014 in association with Mylan Inc," it added.
Shares of Natco Pharma today closed at Rs 621.15 per scrip on BSE, up 2% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%